Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2003

View Archived Issues

Bayer claims new inhibitors of SPEK kinase and their use in cancer therapy

Novel somatostatin sst1 antagonists, their preparation and use reported by Novartis

New series of GSK-3beta inhibitors under study at Janssen

Merz describes new agents with multiple mechanism of action for neurological disorders

Novartis designs new PDE4 inhibitors with utility in asthma

Schering AG researchers design lipoxin A4 analogues for allergy, inflammation, etc.

Mitotic kinesin KSP inhibitors identified at Merck

FDA sets Hemopure review date

FeRx opens phase II/III trial of MTC-doxorubicin

Biphasix interferon alfa cream to enter phase II in 2004

Lundbeck sells stake in Cephalon

Final EVIDENCE data support Rebif over Avonex in MS

Topiglan enters new phase II study for erectile dysfunction

Statin-derived LFA-1 inhibitor proves effective as an immunosuppressant in mice

Novartis presents efficacy and safety data for fully human anti-CD154 MAb

Memantine plus donepezil improves cognition in Alzheimer's disease

Escitalopram reported safe and effective in anxiety and depressive disorders

Influence of sildenafil on duodenal function and cirrhotic portal hemodynamics

Ciclesonide safe and equieffective to budesonide in the management of asthma

Tiagabine clinical trial results presented in San Francisco

Potential agent for prostate cancer available for licensing from BTG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...